These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 24894343)

  • 41. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
    De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutational analysis of BRCA1/2 gene and pathologic characteristics from Kazakh population with sporadic breast cancer in northwestern China.
    Yang SY; Aisimutula D; Li HF; Hu Y; Du X; Li J; Luan MX
    Genet Mol Res; 2015 Oct; 14(4):13151-61. PubMed ID: 26535628
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas.
    Akbari MR; Donenberg T; Lunn J; Curling D; Turnquest T; Krill-Jackson E; Zhang S; Narod SA; Hurley J
    Clin Genet; 2014 Jan; 85(1):64-7. PubMed ID: 23458327
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
    BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
    Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
    Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
    Menes TS; Terry MB; Goldgar D; Andrulis IL; Knight JA; John EM; Liao Y; Southey M; Miron A; Chung W; Buys SS
    Breast Cancer Res Treat; 2015 Jun; 151(3):653-60. PubMed ID: 25975955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic alterations in sporadic triple negative breast cancer.
    Pop LA; Cojocneanu-Petric RM; Pileczki V; Morar-Bolba G; Irimie A; Lazar V; Lombardo C; Paradiso A; Berindan-Neagoe I
    Breast; 2018 Apr; 38():30-38. PubMed ID: 29202330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [BRCA1/2 gene mutation and clinicopathologic features of triple negative breast cancer].
    Ma ZP; Wang W; Zhang W
    Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):397-400. PubMed ID: 27256048
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.
    Wong ES; Shekar S; Chan CH; Hong LZ; Poon SY; Silla T; Lin C; Kumar V; Davila S; Voorhoeve M; Thike AA; Ho GH; Yap YS; Tan PH; Tan MH; Ang P; Lee AS
    PLoS One; 2015; 10(7):e0134408. PubMed ID: 26221963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence and differentiation of hereditary breast and ovarian cancers in Japan.
    Nakamura S; Takahashi M; Tozaki M; Nakayama T; Nomizu T; Miki Y; Murakami Y; Aoki D; Iwase T; Nishimura S; Yamauchi H; Ohsumi S; Baba S; Shimizu T
    Breast Cancer; 2015 Sep; 22(5):462-8. PubMed ID: 24249303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinicopathological Features of BRCA1/2 Mutation-Positive Breast Cancer.
    Paik HJ; Jung YJ; Kim DI; Lee S; Jung CS; Kang SK; Kim JJ; Oh SY; Joo JH; Kim HY
    Oncology; 2021; 99(8):499-506. PubMed ID: 34098565
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.
    Villarreal-Garza C; Weitzel JN; Llacuachaqui M; Sifuentes E; Magallanes-Hoyos MC; Gallardo L; Alvarez-Gómez RM; Herzog J; Castillo D; Royer R; Akbari M; Lara-Medina F; Herrera LA; Mohar A; Narod SA
    Breast Cancer Res Treat; 2015 Apr; 150(2):389-94. PubMed ID: 25716084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study.
    Son BH; Ahn SH; Kim SW; Kang E; Park SK; Lee MH; Noh WC; Kim LS; Jung Y; Kim KS; Noh DY; Moon BI; Suh YJ; Lee JE; Choi DH; Kim SY; Jung SH; Yom CK; Lee H; Yang JH;
    Breast Cancer Res Treat; 2012 Jun; 133(3):1143-52. PubMed ID: 22382806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.
    Pellegrino B; Bella M; Michiara M; Zanelli P; Naldi N; Porzio R; Bortesi B; Boggiani D; Zanoni D; Camisa R; Neri TM; Pinto C; Musolino A
    Acta Biomed; 2016 May; 87(1):54-63. PubMed ID: 27163896
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
    Spurdle AB; Couch FJ; Parsons MT; McGuffog L; Barrowdale D; Bolla MK; Wang Q; Healey S; Schmutzler R; Wappenschmidt B; Rhiem K; Hahnen E; Engel C; Meindl A; Ditsch N; Arnold N; Plendl H; Niederacher D; Sutter C; Wang-Gohrke S; Steinemann D; Preisler-Adams S; Kast K; Varon-Mateeva R; Ellis S; Frost D; Platte R; Perkins J; Evans DG; Izatt L; Eeles R; Adlard J; Davidson R; Cole T; Scuvera G; Manoukian S; Bonanni B; Mariette F; Fortuzzi S; Viel A; Pasini B; Papi L; Varesco L; Balleine R; Nathanson KL; Domchek SM; Offitt K; Jakubowska A; Lindor N; Thomassen M; Jensen UB; Rantala J; Borg Å; Andrulis IL; Miron A; Hansen TV; Caldes T; Neuhausen SL; Toland AE; Nevanlinna H; Montagna M; Garber J; Godwin AK; Osorio A; Factor RE; Terry MB; Rebbeck TR; Karlan BY; Southey M; Rashid MU; Tung N; Pharoah PD; Blows FM; Dunning AM; Provenzano E; Hall P; Czene K; Schmidt MK; Broeks A; Cornelissen S; Verhoef S; Fasching PA; Beckmann MW; Ekici AB; Slamon DJ; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Chang-Claude J; Flesch-Janys D; Rudolph A; Seibold P; Aittomäki K; Muranen TA; Heikkilä P; Blomqvist C; Figueroa J; Chanock SJ; Brinton L; Lissowska J; Olson JE; Pankratz VS; John EM; Whittemore AS; West DW; Hamann U; Torres D; Ulmer HU; Rüdiger T; Devilee P; Tollenaar RA; Seynaeve C; Van Asperen CJ; Eccles DM; Tapper WJ; Durcan L; Jones L; Peto J; dos-Santos-Silva I; Fletcher O; Johnson N; Dwek M; Swann R; Bane AL; Glendon G; Mulligan AM; Giles GG; Milne RL; Baglietto L; McLean C; Carpenter J; Clarke C; Scott R; Brauch H; Brüning T; Ko YD; Cox A; Cross SS; Reed MW; Lubinski J; Jaworska-Bieniek K; Durda K; Gronwald J; Dörk T; Bogdanova N; Park-Simon TW; Hillemanns P; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Burwinkel B; Marme F; Surovy H; Yang R; Anton-Culver H; Ziogas A; Hooning MJ; Collée JM; Martens JW; Tilanus-Linthorst MM; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Grip M; Lindblom A; Margolin S; Joseph V; Robson M; Rau-Murthy R; González-Neira A; Arias JI; Zamora P; Benítez J; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Peterlongo P; Zaffaroni D; Barile M; Capra F; Radice P; Teo SH; Easton DF; Antoniou AC; Chenevix-Trench G; Goldgar DE; ; ; ; ;
    Breast Cancer Res; 2014 Dec; 16(6):3419. PubMed ID: 25857409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine.
    Samusieva A; Serga S; Klymenko S; Rybchenko L; Klimuk B; Zakhartseva L; Gorovenko N; Lobanova O; Rossokha Z; Fishchuk L; Levkovich N; Medvedieva N; Popova O; Cheshuk V; Inomistova M; Khranovska N; Skachkova O; Michailovich Y; Ponomarova O; Kozeretska I
    Breast Cancer Res Treat; 2022 Oct; 195(3):453-459. PubMed ID: 35930098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors.
    Hata C; Nakaoka H; Xiang Y; Wang D; Yang A; Liu D; Liu F; Zou Q; Wei L; Zheng K; Inoue I; You H
    J Hum Genet; 2020 Jul; 65(7):577-587. PubMed ID: 32029870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
    Ryu JM; Choi HJ; Kim I; Nam SJ; Kim SW; Yu J; Lee SK; Choi DH; Park YH; Kim JW; Seo JS; Park JH; Lee JE; Kim SW;
    Breast Cancer Res Treat; 2019 Jan; 173(2):385-395. PubMed ID: 30350268
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China.
    Li YT; Ni D; Yang L; Zhao Q; Ou JH
    Eur J Med Res; 2014 Jun; 19(1):35. PubMed ID: 24961674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.